BioSpace News Archive

Axsome Therapeutics, Inc. announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, Nov. 28, 2023, from 9:30 a.m. - 9:55 a.m. Eastern Time at the Lotte New York Palace in New York City.

Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, announced that management will participate in a fireside discussion at the 35th Annual Piper Sandler Healthcare Conference in New York City on Tuesday, November 28, 2023, at 3:30 p.m. ET.

BioCryst Pharmaceuticals, Inc. announced that the Spanish Ministry for Health has granted marketing authorization for oral, once-daily ORLADEYO® for the routine prevention of recurrent hereditary angioedema attacks in HAE patients 12 years and older.

Sapient Therapeutics Ltd is pleased to announce the successful completion of its Phase 1 Part A comparative trial evaluating the safety and pharmacokinetics of its innovative solid dose prescription cannabidiol (CBD), SAP021.

Vividion Therapeutics, Inc. has been recognized as a Top Workplaces 2023 award winner by the San Diego Union-Tribune for the second year in a row.

Novocure (NASDAQ: NVCR) announced today that management will participate in the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023.

Panavance Therapeutics Inc. announced publication of positive data in the peer-reviewed International Journal of Molecular Sciences in a manuscript titled, “In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes.”1 The publication by Gambichler, et al.

Revive Therapeutics Ltd. provides an update on the development of a next generation lyophilized formulation of Bucillamine.

Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Erik Penser Bank Company Event on Thursday, November 23, at 10.10 CET.

Connect Biopharma Holdings Limited nannounced positive topline results from the Stage 2 of its China pivotal trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe atopic dermatitis.